Novel Transcription Factor Regulating TNF-alpha

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		99-07
IP Type:		Licensable Technology
Title:		Novel Transcription Factor Regulating TNF-alpha
Inventor:		Amar, Salomon
Summary:		This invention discloses an isolated polypeptide referred to as the LITAF protein. Polypeptides of human origin are specifically provided and the nucleic acid sequence which encodes the LITAF protein is also disclosed. Several methods of inhibiting LITAF dependent induction of TNF-alpha gene expression in a cell are provided. Administration of a LITAF inhibitor can be performed as a therapeutic method for treating a patient with a disease associated with chronic inflammation. Such diseases include rheumatoid arthritis, gum disease, CrohnÕs disease, and graft-versus-host disease. Therapeutic methods for treating a patient with a disease in which TNF-alpha plays a role in pathology are also provided. Examples of such diseases are diabetes mellitus, cancer, cachexia, breast cancer, HIV, sepsis, malaria, trypanmiasis and asthma.
Tech Type:		Therapeutics - Methods \| Therapeutics - Methods \| Therapeutics - Drugs \| Therapeutics - Drugs \| Therapeutics - Drugs \| Therapeutics - Drugs
URL:		http://ctf-fmfe.bu.edu/BU9907.pdf
Contact:		Ashley J. Stevens, cives@bu.edu, 617 358 4550
Organization:		Boston University

Display all intellectual properties for Amar, Salomon
Display all intellectual properties for Boston University